Our Programs

Leading the way to novel drugs for autoimmune, inflammatory and aging-related conditions, safe enough for chronic use by fragile population, like children, cancer patients, the elderly


Target disease Preclin Phase 1 Phase 2 Phase 3 Rights
LH-8 (Topical)
Pediatric Alopecia Areata
LH-4 (Topical)
Chemotherapy Induced Alopecia
LH-10 (Oral)
Cancer Related Fatigue


Autoimmune diseases

Pediatric Alopecia Areata (LH-8)

LH-8 (Topical Coacillium 21%) is currently in a Phase 2/3 pivotal study, aims to be the first treatment for Pediatric Alopecia Areata (AA). Pediatric AA is a chronic, debilitating autoimmune skin disease that causes hair loss on the scalp, face and sometimes on other areas of the body. Both genders and all ethnic groups can develop alopecia areata and can be different for every child who has it.

Trial data


About our trials About the condition


Oncology Supportive Care

Chemotherapy Induced Alopecia (LH-4)

LH-4 (Topical Coacillium 42%) aims to be the first treatment for Chemotherapy Induced Alopecia (CIA). Alopecia is one of the most common adverse events caused by numerous chemotherapy drugs. While not a life-threatening event, it has a significantly negative psychological and social impact, with repercussions on various aspects of patients quality of life. We have several trials and the program is currently in Ph 2.

About the condition



Oncology Supportive Care

Cancer Related Fatigue (LH-10)

LH-10 (Oral Coacillium) has completed one Pre-clinical study in mice, aims to be the first treatment for Cancer Related Fatigue (CRF). It is the most commonly reported symptom in patients and has a deep consequence on the patient's quality of life, including physical, psychosocial, and economic/occupational aspects. CRF arises from the cancer itself or can be a side effect of cancer treatments.

About the condition

Collaborations & Partners